• +971551792927
  • info-ucg@utilitarianconferences.com
Login
WhatsApp

Track 34: Artificial Intelligence in Drug Discovery

Track 34: Artificial Intelligence in Drug Discovery

Artificial Intelligence in Drug Discovery

Artificial Intelligence (AI) is revolutionizing the landscape of drug discovery, accelerating the path from concept to clinic with unprecedented precision and efficiency. By leveraging advanced algorithms, machine learning, and deep neural networks, AI enables researchers to analyze vast datasets, predict molecular interactions, and identify promising drug candidates in a fraction of the time and cost of traditional methods.

AI-driven platforms can uncover hidden patterns in genomic, proteomic, and clinical data, guiding the rational design of molecules and optimizing lead compounds with greater accuracy. From target identification and validation to virtual screening, de novo drug design, and predictive toxicology, AI is transforming each stage of the drug discovery pipeline.

In addition to speed and scalability, AI enhances success rates and decision-making, reducing the risk of late-stage failures and improving ROI for pharmaceutical development. As models continue to learn and adapt, AI promises not just faster discoveries, but smarter, safer, and more personalized therapeutics.

With AI, the future of drug discovery is not only faster — it's smarter, safer, and more human-centric.